REFERENCES
1. GBD 2023 Cancer Collaborators. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 2025, 406, 1565-86.
2. Schwartzberg, L.; Kim, E. S.; Liu, D.; Schrag, D. Precision oncology: who, how, what, when, and when not? Am. Soc. Clin. Oncol. Educ. Book. 2017, 37, 160-9.
3. El-Deiry, W. S.; Goldberg, R. M.; Lenz, H. J.; et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA. Cancer. J. Clin. 2019, 69, 305-43.
4. Kelkar, S. S.; Reineke, T. M. Theranostics: combining imaging and therapy. Bioconjug. Chem. 2011, 22, 1879-903.
6. Gerlinger, M.; Rowan, A. J.; Horswell, S.; et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366, 883-92.
7. Marusyk, A.; Janiszewska, M.; Polyak, K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer. Cell. 2020, 37, 471-84.
8. Bardelli, A.; Pantel, K. Liquid biopsies, what we do not know (yet). Cancer. Cell. 2017, 31, 172-9.
9. Collins, F. S.; Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 2015, 372, 793-5.
10. Choi, K. Y.; Liu, G.; Lee, S.; Chen, X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 2012, 4, 330-42.
11. Rowe, S. P.; Pomper, M. G. Molecular imaging in oncology: current impact and future directions. CA. Cancer. J. Clin. 2022, 72, 333-52.
12. O’Connor, J. P. B.; Aboagye, E. O.; Adams, J. E.; et al. Imaging biomarker roadmap for cancer studies. Nat. Rev. Clin. Oncol. 2017, 14, 169-86.
13. Mehta, P.; Sharma, M.; Devi, M. Hydrogels: an overview of its classifications, properties, and applications. J. Mech. Behav. Biomed. Mater. 2023, 147, 106145.
14. Li, J.; Mooney, D. J. Designing hydrogels for controlled drug delivery. Nat. Rev. Mater. 2016, 1, 16071.
15. Sun, Z.; Song, C.; Wang, C.; Hu, Y.; Wu, J. Hydrogel-based controlled drug delivery for cancer treatment: a review. Mol. Pharm. 2020, 17, 373-91.
16. Solanki, R.; Bhatia, D. Stimulus-responsive hydrogels for targeted cancer therapy. Gels 2024, 10, 440.
17. Masaeli, E.; Srinivasan, S.; Rajabzadeh, A. R. Transforming cancer diagnosis and therapy through fluorescent hydrogels: a review. Adv. Healthc. Mater. 2026, 15, e02577.
18. Sampath, B.; Charles, J. Theranostic magnetic hydrogels for treatment, recurrence prevention, tumour modelling and emerging applications in breast cancer management: a review. Int. J. Biol. Macromol. 2026, 359, 151874.
19. Lee, K. K.; Go, K.; Lee, E.; et al. Multifunctional hydrogels for advanced cancer treatment: diagnostic imaging and therapeutic modalities. Gels 2025, 11, 426.
20. Hoare, T. R.; Kohane, D. S. Hydrogels in drug delivery: progress and challenges. Polymer 2008, 49, 1993-2007.
21. Peppas, N. A.; Bures, P.; Leobandung, W.; Ichikawa, H. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 2000, 50, 27-46.
22. Tibbitt, M. W.; Anseth, K. S. Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnol. Bioeng. 2009, 103, 655-63.
23. Drury, J. L.; Mooney, D. J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials 2003, 24, 4337-51.
24. Zhu, H.; Zheng, J.; Oh, X. Y.; et al. Nanoarchitecture-integrated hydrogel systems toward therapeutic applications. ACS. Nano. 2023, 17, 7953-78.
25. Lu, P.; Ruan, D.; Huang, M.; et al. Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. Signal. Transduct. Target. Ther. 2024, 9, 166.
26. Guo, L.; Fu, Z.; Li, H.; et al. Smart hydrogel: a new platform for cancer therapy. Adv. Colloid. Interface. Sci. 2025, 340, 103470.
27. Lee, K. Y.; Mooney, D. J. Alginate: properties and biomedical applications. Prog. Polym. Sci. 2012, 37, 106-26.
28. Augst, A. D.; Kong, H. J.; Mooney, D. J. Alginate hydrogels as biomaterials. Macromol. Biosci. 2006, 6, 623-33.
29. Rowley, J. A.; Madlambayan, G.; Mooney, D. J. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 1999, 20, 45-53.
30. Dash, M.; Chiellini, F.; Ottenbrite, R.; Chiellini, E. Chitosan - a versatile semi-synthetic polymer in biomedical applications. Prog. Polym. Sci. 2011, 36, 981-1014.
31. Croisier, F.; Jérôme, C. Chitosan-based biomaterials for tissue engineering. Eur. Polym. J. 2013, 49, 780-92.
32. Sockett, K. A.; Jiang, N. C.; Ungolan, P.; Niu, J.; Grinstaff, M. W. Advancements in hyaluronic acid synthetic methodologies and their translational relevance. Chem. Rev. 2026, 126, 3224-86.
33. Burdick, J. A.; Prestwich, G. D. Hyaluronic acid hydrogels for biomedical applications. Adv. Mater. 2011, 23, H41-56.
34. Highley, C. B.; Prestwich, G. D.; Burdick, J. A. Recent advances in hyaluronic acid hydrogels for biomedical applications. Curr. Opin. Biotechnol. 2016, 40, 35-40.
35. Yue, K.; Trujillo-de Santiago, G.; Alvarez, M. M.; Tamayol, A.; Annabi, N.; Khademhosseini, A. Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels. Biomaterials 2015, 73, 254-71.
36. Caliari, S. R.; Burdick, J. A. A practical guide to hydrogels for cell culture. Nat. Methods. 2016, 13, 405-14.
37. Gonzalez-Obeso, C.; Jane Hartzell, E.; Albert Scheel, R.; Kaplan, D. L. Delivering on the promise of recombinant silk-inspired proteins for drug delivery. Adv. Drug. Deliv. Rev. 2023, 192, 114622.
38. Canal, T.; Peppas, N. A. Correlation between mesh size and equilibrium degree of swelling of polymeric networks. J. Biomed. Mater. Res. 1989, 23, 1183-93.
39. Zustiak, S. P.; Leach, J. B. Hydrolytically degradable poly(ethylene glycol) hydrogel scaffolds with tunable degradation and mechanical properties. Biomacromolecules 2010, 11, 1348-57.
40. Raeber, G. P.; Lutolf, M. P.; Hubbell, J. A. Molecularly engineered PEG hydrogels: a novel model system for proteolytically mediated cell migration. Biophys. J. 2005, 89, 1374-88.
41. Rehmann, M. S.; Skeens, K. M.; Kharkar, P. M.; et al. Tuning and predicting mesh size and protein release from step growth hydrogels. Biomacromolecules 2017, 18, 3131-42.
42. Lutolf, M.; Raeber, G.; Zisch, A.; Tirelli, N.; Hubbell, J. Cell‐responsive synthetic hydrogels. Adv. Mater. 2003, 15, 888-92.
43. Gill, B. J.; Gibbons, D. L.; Roudsari, L. C.; et al. A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer. Res. 2012, 72, 6013-23.
44. Li, J. K.; Wang, N.; Wu, X. S. Poly(vinyl alcohol) nanoparticles prepared by freezing-thawing process for protein/peptide drug delivery. J. Control. Release. 1998, 56, 117-26.
45. Oh, N. G.; Hwang, S. Y.; Na, Y. H. Fabrication of a PVA-based hydrogel microneedle patch. ACS. Omega. 2022, 7, 25179-85.
46. Nguyen, H. X.; Bozorg, B. D.; Kim, Y.; et al. Poly (vinyl alcohol) microneedles: fabrication, characterization, and application for transdermal drug delivery of doxorubicin. Eur. J. Pharm. Biopharm. 2018, 129, 88-103.
47. Jain, M.; Pansuriya, R.; Thakur, R.; et al. PVA/guanidinium oleate transdermal patch as a pH-responsive drug delivery system for the localized and targeted delivery of anticancer drugs. Mater. Adv. 2024, 5, 1998-2011.
48. Tilghman, R. W.; Cowan, C. R.; Mih, J. D.; et al. Matrix rigidity regulates cancer cell growth and cellular phenotype. PLoS. One. 2010, 5, e12905.
49. Gao, Y.; Ren, F.; Ding, B.; et al. A thermo-sensitive PLGA-PEG-PLGA hydrogel for sustained release of docetaxel. J. Drug. Target. 2011, 19, 516-27.
50. Ma, H.; He, C.; Cheng, Y.; et al. PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment. Biomaterials 2014, 35, 8723-34.
51. Zhang, S.; Holmes, T.; Lockshin, C.; Rich, A.; New Collective Author. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 3334-8.
52. Hartgerink, J. D.; Beniash, E.; Stupp, S. I. Self-assembly and mineralization of peptide-amphiphile nanofibers. Science 2001, 294, 1684-8.
53. Um, S. H.; Lee, J. B.; Park, N.; Kwon, S. Y.; Umbach, C. C.; Luo, D. Enzyme-catalysed assembly of DNA hydrogel. Nat. Mater. 2006, 5, 797-801.
54. Xing, Y.; Cheng, E.; Yang, Y.; et al. Self-assembled DNA hydrogels with designable thermal and enzymatic responsiveness. Adv. Mater. 2011, 23, 1117-21.
55. Rodell, C. B.; Kaminski, A. L.; Burdick, J. A. Rational design of network properties in guest-host assembled and shear-thinning hyaluronic acid hydrogels. Biomacromolecules 2013, 14, 4125-34.
56. Lin, C. C.; Anseth, K. S. PEG hydrogels for the controlled release of biomolecules in regenerative medicine. Pharm. Res. 2009, 26, 631-43.
57. Censi, R.; Di Martino, P.; Vermonden, T.; Hennink, W. E. Hydrogels for protein delivery in tissue engineering. J. Control. Release. 2012, 161, 680-92.
58. Ding, X.; Wang, Y. Weak bond-based injectable and stimuli responsive hydrogels for biomedical applications. J. Mater. Chem. B. 2017, 5, 887-906.
59. Jalalvandi, E.; Shavandi, A. Shear thinning/self-healing hydrogel based on natural polymers with secondary photocrosslinking for biomedical applications. J. Mech. Behav. Biomed. Mater. 2019, 90, 191-201.
60. Shi, Y.; Li, D.; He, C.; Chen, X. Design of an injectable polypeptide hydrogel depot containing the immune checkpoint blocker anti-PD-L1 and doxorubicin to enhance antitumor combination therapy. Macromol. Biosci. 2021, 21, e2100049.
61. Siboro, S. A. P.; Anugrah, D. S. B.; Ramesh, K.; Park, S. H.; Kim, H. R.; Lim, K. T. Tunable porosity of covalently crosslinked alginate-based hydrogels and its significance in drug release behavior. Carbohydr. Polym. 2021, 260, 117779.
62. Fairbanks, B. D.; Schwartz, M. P.; Bowman, C. N.; Anseth, K. S. Photoinitiated polymerization of PEG-diacrylate with lithium phenyl-2,4,6-trimethylbenzoylphosphinate: polymerization rate and cytocompatibility. Biomaterials 2009, 30, 6702-7.
63. Shin, G. R.; Kim, H. E.; Ju, H. J.; et al. Injectable click-crosslinked hydrogel containing resveratrol to improve the therapeutic effect in triple negative breast cancer. Mater. Today. Bio. 2022, 16, 100386.
64. Cao, D.; Zhang, X.; Akabar, M. D.; et al. Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer. Artif. Cells. Nanomed. Biotechnol. 2019, 47, 181-91.
65. Nguyen, A. K.; Goering, P. L.; Reipa, V.; Narayan, R. J. Toxicity and photosensitizing assessment of gelatin methacryloyl-based hydrogels photoinitiated with lithium phenyl-2,4,6-trimethylbenzoylphosphinate in human primary renal proximal tubule epithelial cells. Biointerphases 2019, 14, 021007.
66. Nguyen, A. K.; Goering, P. L.; Elespuru, R. K.; Sarkar Das, S.; Narayan, R. J. The photoinitiator lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate with exposure to 405 nm light is cytotoxic to mammalian cells but not mutagenic in bacterial reverse mutation assays. Polymers 2020, 12, 1489.
67. Yesilyurt, V.; Webber, M. J.; Appel, E. A.; Godwin, C.; Langer, R.; Anderson, D. G. Injectable self-healing glucose-responsive hydrogels with pH-regulated mechanical properties. Adv. Mater. 2016, 28, 86-91.
68. Huang, Z.; Delparastan, P.; Burch, P.; Cheng, J.; Cao, Y.; Messersmith, P. B. Injectable dynamic covalent hydrogels of boronic acid polymers cross-linked by bioactive plant-derived polyphenols. Biomater. Sci. 2018, 6, 2487-95.
69. Deng, C. C.; Brooks, W. L. A.; Abboud, K. A.; Sumerlin, B. S. Boronic acid-based hydrogels undergo self-healing at neutral and acidic pH. ACS. Macro. Lett. 2015, 4, 220-4.
70. Lee, F.; Chung, J. E.; Kurisawa, M. An injectable enzymatically crosslinked hyaluronic acid- hydrogel system with independent tuning of mechanical strength and gelation rate. Soft. Matter. 2008, 4, 880-7.
71. Kurisawa, M.; Lee, F.; Wang, L.; Chung, J. E. Injectable enzymatically crosslinked hydrogel system with independent tuning of mechanical strength and gelation rate for drug delivery and tissue engineering. J. Mater. Chem. 2010, 20, 5371.
72. Cheng, E.; Xing, Y.; Chen, P.; et al. A pH-triggered, fast-responding DNA hydrogel. Angew. Chem. Int. Ed. Engl. 2009, 48, 7660-3.
73. Yang, H.; Liu, H.; Kang, H.; Tan, W. Engineering target-responsive hydrogels based on aptamer-target interactions. J. Am. Chem. Soc. 2008, 130, 6320-1.
74. Katopodi, T.; Petanidis, S.; Floros, G.; Porpodis, K.; Kosmidis, C. Hybrid nanogel drug delivery systems: transforming the tumor microenvironment through tumor tissue editing. Cells 2024, 13, 908.
75. Liu, Y.; Chen, L.; Shi, Q.; Zhao, Q.; Ma, H. Tumor microenvironment-responsive polypeptide nanogels for controlled antitumor drug delivery. Front. Pharmacol. 2021, 12, 748102.
76. Zhang, H.; Ba, S.; Lee, J. Y.; Xie, J.; Loh, T. P.; Li, T. Cancer biomarker-triggered disintegrable DNA nanogels for intelligent drug delivery. Nano. Lett. 2020, 20, 8399-407.
77. Xu, X.; Jiang, Y.; Lu, C. Self-assembled ATP-responsive DNA nanohydrogel for specifically activated fluorescence imaging and chemotherapy in cancer cells. Anal. Chem. 2022, 94, 10221-6.
78. Shang, J.; Yu, S.; Li, R.; He, Y.; Wang, Y.; Wang, F. Bioorthogonal disassembly of hierarchical DNAzyme nanogel for high-performance intracellular microRNA imaging. Nano. Lett. 2023, 23, 1386-94.
79. Su, M.; Zhu, Y.; Chen, J.; et al. Microfluidic synthesis of manganese-alginate nanogels with self-supplying H2O2 capability for synergistic chemo/chemodynamic therapy and boosting anticancer immunity. Chem. Eng. J. 2022, 435, 134926.
80. Sanati, M.; Amin, Yavari. S. Liposome-integrated hydrogel hybrids: promising platforms for cancer therapy and tissue regeneration. J. Control. Release. 2024, 368, 703-27.
81. Binaymotlagh, R.; Hajareh Haghighi, F.; Chronopoulou, L.; Palocci, C. Liposome-hydrogel composites for controlled drug delivery applications. Gels 2024, 10, 284.
82. GuhaSarkar, S.; Pathak, K.; Sudhalkar, N.; et al. Synergistic locoregional chemoradiotherapy using a composite liposome-in-gel system as an injectable drug depot. Int. J. Nanomedicine. 2016, 11, 6435-48.
83. Mao, Y.; Li, X.; Chen, G.; Wang, S. Thermosensitive hydrogel system with paclitaxel liposomes used in localized drug delivery system for in situ treatment of tumor: better antitumor efficacy and lower toxicity. J. Pharm. Sci. 2016, 105, 194-204.
84. Bouché, M.; Dong, Y. C.; Sheikh, S.; et al. Novel treatment for glioblastoma delivered by a radiation responsive and radiopaque hydrogel. ACS. Biomater. Sci. Eng. 2021, 7, 3209-20.
85. Huang, S.; Hong, X.; Zhao, M.; et al. Nanocomposite hydrogels for biomedical applications. Bioeng. Transl. Med. 2022, 7, e10315.
86. Wang, C.; Zhao, N.; Huang, Y.; He, R.; Xu, S.; Yuan, W. Coordination of injectable self-healing hydrogel with Mn-Zn ferrite@mesoporous silica nanospheres for tumor MR imaging and efficient synergistic magnetothermal-chemo-chemodynamic therapy. Chem. Eng. J. 2020, 401, 126100.
87. Yue, J.; Miao, P.; Li, L.; Yan, R.; Dong, W. F.; Mei, Q. Injectable carbon dots-based hydrogel for combined photothermal therapy and photodynamic therapy of cancer. ACS. Appl. Mater. Interfaces. 2022, 14, 49582-91.
88. Vaziri, A.; Maia, R.; Zhang, P.; et al. Granular hydrogels as modular biomaterials: from structural design to biological responses. Adv. Healthc. Mater. 2026, 15, e02462.
89. Daly, A. C.; Riley, L.; Segura, T.; Burdick, J. A. Hydrogel microparticles for biomedical applications. Nat. Rev. Mater. 2020, 5, 20-43.
90. Sinclair, A.; O’Kelly, M. B.; Bai, T.; Hung, H. C.; Jain, P.; Jiang, S. Self-healing zwitterionic microgels as a versatile platform for malleable cell constructs and injectable therapies. Adv. Mater. 2018, 30, e1803087.
91. Zhong, Z.; Gan, L.; Feng, Z.; et al. Hydrogel local drug delivery systems for postsurgical management of tumors: Status Quo and perspectives. Mater. Today. Bio. 2024, 29, 101308.
92. Zhang, J.; Chen, C.; Li, A.; et al. Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection. Nat. Nanotechnol. 2021, 16, 538-48.
93. Fu, Z.; Li, H.; Xue, P.; et al. Implantable bioresponsive hydrogel prevents local recurrence of breast cancer by enhancing radiosensitivity. Front. Bioeng. Biotechnol. 2022, 10, 881544.
94. Yan, X.; Sun, T.; Song, Y.; et al. In situ thermal-responsive magnetic hydrogel for multidisciplinary therapy of hepatocellular carcinoma. Nano. Lett. 2022, 22, 2251-60.
95. Zhou, J.; Wang, H.; Chen, H.; et al. pH-responsive nanocomposite hydrogel for simultaneous prevention of postoperative adhesion and tumor recurrence. Acta. Biomater. 2023, 158, 228-38.
96. Amatya, R.; Hwang, S.; Park, T.; et al. BSA/silver nanoparticle-loaded hydrogel film for local photothermal treatment of skin cancer. Pharm. Res. 2021, 38, 873-83.
97. Seo, J. Y.; Lee, B.; Kang, T. W.; et al. Electrostatically interactive injectable hydrogels for drug delivery. Tissue. Eng. Regen. Med. 2018, 15, 513-20.
98. Akther, F.; Little, P.; Li, Z.; Nguyen, N. T.; Ta, H. T. Hydrogels as artificial matrices for cell seeding in microfluidic devices. RSC. Adv. 2020, 10, 43682-703.
99. Shin, G. R.; Kim, H. E.; Kim, J. H.; Choi, S.; Kim, M. S. Advances in injectable in situ-forming hydrogels for intratumoral treatment. Pharmaceutics 2021, 13, 1953.
100. Han, X.; Meng, X.; Wu, Z.; Wu, Z.; Qi, X. Dynamic imine bond cross-linked self-healing thermosensitive hydrogels for sustained anticancer therapy via intratumoral injection. Mater. Sci. Eng. C. Mater. Biol. Appl. 2018, 93, 1064-72.
101. Wang, Y.; Wang, S.; Hu, W.; et al. In situ hydrogels prepared by photo-initiated crosslinking of acrylated polymers for local delivery of antitumor drugs. J. Pharm. Sci. 2023, 112, 1863-71.
102. Attama, A. A.; Nnamani, P. O.; Onokala, O. B.; Ugwu, A. A.; Onugwu, A. L. Nanogels as target drug delivery systems in cancer therapy: a review of the last decade. Front. Pharmacol. 2022, 13, 874510.
103. Li, X.; Li, H.; Zhang, C.; Pich, A.; Xing, L.; Shi, X. Intelligent nanogels with self-adaptive responsiveness for improved tumor drug delivery and augmented chemotherapy. Bioact. Mater. 2021, 6, 3473-84.
104. Qian, K.; Ma, Y.; Wan, J.; et al. The studies about doxorubicin-loaded p(N-isopropyl-acrylamide-co-butyl methylacrylate) temperature-sensitive nanogel dispersions on the application in TACE therapies for rabbit VX2 liver tumor. J. Control. Release. 2015, 212, 41-9.
105. Ma, X.; Zhou, W.; Zhang, R.; et al. Minimally invasive injection of biomimetic Nano@Microgel for in situ ovarian cancer treatment through enhanced photodynamic reactions and photothermal combined therapy. Mater. Today. Bio. 2023, 20, 100663.
106. Agrawal, G.; Agrawal, R. Functional microgels: recent advances in their biomedical applications. Small 2018, 14, e1801724.
108. Raza, A.; Khan, A. Q.; Inchakalody, V. P.; et al. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer. J. Exp. Clin. Cancer. Res. 2022, 41, 99.
109. Kim, Y. J.; Min, J. Hydrogel-based technologies in liquid biopsy for the detection of circulating clinical markers: challenges and prospects. Anal. Bioanal. Chem. 2024, 416, 2065-78.
110. Luchini, A.; Geho, D. H.; Bishop, B.; et al. Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano. Lett. 2008, 8, 350-61.
111. Tang, J.; Jia, X.; Li, Q.; et al. A DNA-based hydrogel for exosome separation and biomedical applications. Proc. Natl. Acad. Sci. U. S. A. 2023, 120, e2303822120.
112. Chen, B.; Wang, G.; Huang, C.; et al. A light-induced hydrogel responsive platform to capture and selectively isolate single circulating tumor cells. Nanoscale 2022, 14, 3504-12.
113. Kim, Y. J.; Cho, Y. H.; Min, J.; Han, S. W. Circulating tumor marker isolation with the chemically stable and instantly degradable (CSID) hydrogel immunospheres. Anal. Chem. 2021, 93, 1100-9.
114. Kaniewska, K.; Kowalczyk, A.; Karbarz, M.; Nowicka, A. M. Changes in the volume phase transition temperature of hydrogels for detection of the DNA hybridization process. Analyst 2016, 141, 5815-21.
115. Xu, Y.; Zhang, X.; Luan, C.; Wang, H.; Chen, B.; Zhao, Y. Hybrid hydrogel photonic barcodes for multiplex detection of tumor markers. Biosens. Bioelectron. 2017, 87, 264-70.
116. Sun, S.; Chen, J. Recent advances in hydrogel-based biosensors for cancer detection. ACS. Appl. Mater. Interfaces. 2024, 16, 46988-7002.
117. Lu, H.; Samman, F.; Hasan, E.; Alsulaiman, D. Novabeads: stimuli-responsive signal-amplifying hydrogel microparticles for enzymeless fluorescence-based detection of microRNA biomarkers. Small 2025, 21, e2503990.
118. Ring, A.; Nguyen-Sträuli, B. D.; Wicki, A.; Aceto, N. Biology, vulnerabilities and clinical applications of circulating tumour cells. Nat. Rev. Cancer. 2023, 23, 95-111.
119. Capuozzo, M.; Ferrara, F.; Santorsola, M.; Zovi, A.; Ottaiano, A. Circulating tumor cells as predictive and prognostic biomarkers in solid tumors. Cells 2023, 12, 2590.
120. Portella, L.; Bertolini, G.; Guardascione, G.; et al. CXCL12-loaded-hydrogel (CLG): a new device for metastatic circulating tumor cells (CTCs) capturing and characterization. Heliyon 2024, 10, e35524.
121. Sun, W.; You, X.; Zhao, X.; et al. Precise capture and dynamic release of circulating liver cancer cells with dual-histidine-based cell imprinted hydrogels. Adv. Mater. 2024, 36, e2402379.
122. Dawson, S. J.; Tsui, D. W.; Murtaza, M.; et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 368, 1199-209.
123. Garcia-Murillas, I.; Schiavon, G.; Weigelt, B.; et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 2015, 7, 302ra133.
124. Zhao, X.; Meng, X.; Zeng, X.; He, T.; Chen, J.; Chen, P. Homogeneous extraction-free dual-ctDNA detection via DNA nanomaterial fusion for rapid breast cancer diagnosis. ACS. Nano. 2025, 19, 42066-78.
125. Hou, J.; Wang, Y.; Yuan, W.; et al. Thermosensitive hydrogel-enhanced RPA-CRISPR/Cas12a biosensor for ultrasensitive detection of methylated loci in breast cancer ctDNA. Anal. Chim. Acta. 2026, 1388, 345101.
126. McAlexander, M. A.; Phillips, M. J.; Witwer, K. W. Comparison of methods for miRNA extraction from plasma and quantitative recovery of RNA from cerebrospinal fluid. Front. Genet. 2013, 4, 83.
127. Sourvinou, I. S.; Markou, A.; Lianidou, E. S. Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. J. Mol. Diagn. 2013, 15, 827-34.
128. Jang, W.; Kim, Y. J.; Roh, H. K.; Song, E. L.; Bong, K. W. Hydrogel-based in situ DNA extension assay for multiplexed and rapid detection of microRNA. Anal. Chem. 2025, 97, 7317-24.
129. Chen, D.; Wang, Y.; Wei, Y.; et al. Size-coded hydrogel microbeads for extraction-free serum multi-miRNAs quantifications with machine-learning-aided lung cancer subtypes classification. Nano. Lett. 2025, 25, 453-60.
130. Lin, Y.; Xing, G.; Wu, Z.; et al. Microfluidic-enabled self-directed hydrogel microspheres for multiplexed microRNA assays. Anal. Chem. 2025, 97, 1972-6.
131. Yao, C.; Wang, Q.; Lu, X.; Chen, X.; Li, Z. Hydrogel-based microdroplet ensembles encapsulating multiplexed EXPAR assays for trichromic digital profiling of microRNAs and in-depth classification of primary urethral cancers. Nano. Lett. 2024, 24, 15861-9.
132. Yu, W.; Hurley, J.; Roberts, D.; et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann. Oncol. 2021, 32, 466-77.
133. Xu, X.; Zhang, M.; Zhang, X.; et al. Decoding expression dynamics of protein and transcriptome at the single-cell level in paired picoliter chambers. Anal. Chem. 2022, 94, 8164-73.
134. Miwa, H.; Dimatteo, R.; de Rutte, J.; Ghosh, R.; Di Carlo, D. Single-cell sorting based on secreted products for functionally defined cell therapies. Microsyst. Nanoeng. 2022, 8, 84.
135. Yamagata, C.; Hamazaki, Y.; Nakazato, T.; et al. Oil-sealed RGD-modified alginate hydrogel microwell array for analysis of single-cell-derived extracellular vesicles and particles. Microsyst. Nanoeng. 2025, 11, 238.
136. Lee, S. S.; Kim, H.; Sohn, D. K.; et al. Indocyanine green-loaded injectable alginate hydrogel as a marker for precision cancer surgery. Quant. Imaging. Med. Surg. 2020, 10, 779-88.
137. Linders, D. G. J.; Bijlstra, O. D.; Walker, E.; et al. Ex vivo fluorescence-guided resection margin assessment in breast cancer surgery using a topically applied, cathepsin-activatable imaging agent. Pharmacol. Res. 2024, 209, 107464.
138. Yang, H. Y.; Jang, M. S.; Sun, X. S.; et al. CD44-mediated tumor homing of hyaluronic acid nanogels for hypoxia-activated photodynamic therapy against tumor. Colloids. Surf. B. Biointerfaces. 2023, 228, 113395.
139. Song, P.; Ye, D.; Zuo, X.; et al. DNA hydrogel with aptamer-toehold-based recognition, cloaking, and decloaking of circulating tumor cells for live cell analysis. Nano. Lett. 2017, 17, 5193-8.
140. Chen, T.; Su, L.; Lin, L.; et al. Mesoporous radiosensitized nanoprobe for enhanced NIR-II photoacoustic imaging-guided accurate radio-chemotherapy. Nano. Res. 2022, 15, 4154-63.
141. Vahrmeijer, A. L.; Hutteman, M.; van der Vorst, J. R.; van de Velde, C. J.; Frangioni, J. V. Image-guided cancer surgery using near-infrared fluorescence. Nat. Rev. Clin. Oncol. 2013, 10, 507-18.
142. Saxena, V.; Sadoqi, M.; Shao, J. Degradation kinetics of indocyanine green in aqueous solution. J. Pharm. Sci. 2003, 92, 2090-7.
143. Andreiuk, B.; Reisch, A.; Bernhardt, E.; Klymchenko, A. S. Fighting aggregation-caused quenching and leakage of dyes in fluorescent polymer nanoparticles: universal role of counterion. Chem. Asian. J. 2019, 14, 836-46.
144. Liu, C.; Ruan, C.; Shi, R.; Jiang, B. P.; Ji, S.; Shen, X. C. A near infrared-modulated thermosensitive hydrogel for stabilization of indocyanine green and combinatorial anticancer phototherapy. Biomater. Sci. 2019, 7, 1705-15.
145. Donnelly, R. F.; Singh, T. R.; Garland, M. J.; et al. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Adv. Funct. Mater. 2012, 22, 4879-90.
146. Park, J.; Ku, M.; Kim, E.; et al. CD44-specific supramolecular hydrogels for fluorescence molecular imaging of stem-like gastric cancer cells. Integr. Biol. 2013, 5, 669-72.
147. Yang, J.; Qu, J.; Teng, X.; et al. Tumor microenvironment-responsive hydrogel for direct extracellular ATP imaging-guided surgical resection with clear boundaries. Adv. Healthc. Mater. 2023, 12, e2301084.
148. Walker, E.; Linders, D. G. J.; Abenojar, E.; et al. Formulation of a thermosensitive imaging hydrogel for topical application and rapid visualization of tumor margins in the surgical cavity. Cancers 2022, 14, 3459.
149. Guo, P.; Qi, A.; Shang, W.; et al. Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer. Eur. J. Nucl. Med. Mol. Imaging. 2024, 51, 4165-76.
150. Lee, S. S.; Choi, Y. Near-infrared dye-loaded thermosensitive hydrogels as novel fluorescence tissue markers. Gels 2025, 11, 649.
151. Upputuri, P. K.; Pramanik, M. Photoacoustic imaging in the second near-infrared window: a review. J. Biomed. Opt. 2019, 24, 1-20.
152. Sun, X.; Li, Y.; Liu, X.; Cui, D.; Shi, Y.; Huang, G. Tumor-specific enhanced NIR-II photoacoustic imaging via photothermal and low-pH coactivated AuNR@PNIPAM-VAA nanogel. J. Nanobiotechnology. 2024, 22, 326.
153. Jo, J.; Folz, J.; Gonzalez, M. E.; et al. Personalized oncology by in vivo chemical imaging: photoacoustic mapping of tumor oxygen predicts radiotherapy efficacy. ACS. Nano. 2023, 17, 4396-403.
154. Folz, J.; Jo, J.; Eido, A.; et al. Photoacoustic chemical imaging of tumor microenvironment pH for prediction of chemotherapeutic efficacy in breast cancer. Nano. Lett. 2025, 25, 14808-16.
155. Tyler, B.; Fowers, K. D.; Li, K. W.; et al. A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. J. Neurosurg. 2010, 113, 210-7.
156. Wang, C.; Wang, J.; Zhang, X.; et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci. Transl. Med. 2018, 10, eaan3682.
157. Chen, Q.; Wang, C.; Zhang, X.; et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat. Nanotechnol. 2019, 14, 89-97.
158. Liu, Y.; Han, Y. Y.; Lu, S.; et al. Injectable hydrogel platform with biodegradable Dawson-type polyoxometalate and R848 for combinational photothermal-immunotherapy of cancer. Biomater. Sci. 2022, 10, 1257-66.
159. Zhao, J.; Li, J.; Zhu, C.; et al. Design of phase-changeable and injectable alginate hydrogel for imaging-guided tumor hyperthermia and chemotherapy. ACS. Appl. Mater. Interfaces. 2018, 10, 3392-404.
160. Shi, J.; Kantoff, P. W.; Wooster, R.; Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer. 2017, 17, 20-37.
161. Guo, Y.; Chen, Y.; Wu, Y.; et al. Injectable pH-responsive polypeptide hydrogels for local delivery of doxorubicin. Nanoscale. Adv. 2024, 6, 6420-32.
162. Shi, Y.; Zhu, H.; Xu, S.; et al. Injectable doxorubicin-loaded hyaluronic acid-based hydrogel for locoregional therapy and inhibiting metastasis of breast cancer. Colloids. Surf. B. Biointerfaces. 2025, 247, 114433.
163. Zhang, Q.; Zhang, Y.; Chen, H.; et al. Injectable hydrogel with doxorubicin-loaded ZIF-8 nanoparticles for tumor postoperative treatments and wound repair. Sci. Rep. 2024, 14, 9983.
164. Mohite, P.; Puri, A.; Munde, S.; et al. Hydrogel-forming microneedles in the management of dermal disorders through a non-invasive process: a review. Gels 2024, 10, 719.
165. Zhu, L.; Qiao, G.; Gao, H.; Jiang, A.; Zhang, L.; Wang, X. Enhancing melanoma therapy with hydrogel microneedles. Front. Oncol. 2025, 15, 1590534.
166. Wang, C.; Ye, Y.; Hochu, G. M.; Sadeghifar, H.; Gu, Z. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano. Lett. 2016, 16, 2334-40.
167. Zhang, Z.; Zhang, Z.; Zeng, W.; Li, Y.; Zhu, C. A hyaluronic acid-based dual-functional hydrogel microneedle system for sequential melanoma ablation and skin regeneration. Int. J. Biol. Macromol. 2024, 283, 138039.
168. Messing, E. M.; Tangen, C. M.; Lerner, S. P.; et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA 2018, 319, 1880-8.
169. Zheng, B.; Zhang, H.; Wang, J.; et al. A mucoadhesive-to-penetrating nanomotors-in-hydrogel system for urothelium-oriented intravesical drug delivery. J. Nanobiotechnology. 2024, 22, 560.
170. Sahin, U.; Derhovanessian, E.; Miller, M.; et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017, 547, 222-6.
171. Ott, P. A.; Hu, Z.; Keskin, D. B.; et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017, 547, 217-21.
172. Gong, N.; Alameh, M. G.; El-Mayta, R.; Xue, L.; Weissman, D.; Mitchell, M. J. Enhancing in situ cancer vaccines using delivery technologies. Nat. Rev. Drug. Discov. 2024, 23, 607-25.
173. Sakuishi, K.; Apetoh, L.; Sullivan, J. M.; Blazar, B. R.; Kuchroo, V. K.; Anderson, A. C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207, 2187-94.
174. Fan, S.; Han, H.; Yan, Z.; Lu, Y.; He, B.; Zhang, Q. Lipid-based nanoparticles for cancer immunotherapy. Med. Rev. 2023, 3, 230-69.
175. Mikhail, A. S.; Morhard, R.; Mauda-Havakuk, M.; Kassin, M.; Arrichiello, A.; Wood, B. J. Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer. Adv. Drug. Deliv. Rev. 2023, 202, 115083.
176. Pechnikova, N. A.; Aggeli, A.; Latypova, A. A.; et al. Implantable biomaterials for cancer immunotherapies. Adv. Funct. Mater. 2025, 35, 2416813.
177. Jia, W.; Wu, Y.; Xie, Y.; Yu, M.; Chen, Y. Advanced polymeric nanoparticles for cancer immunotherapy: materials engineering, immunotherapeutic mechanism and clinical translation. Adv. Mater. 2025, 37, e2413603.
178. Qiu, W.; Zheng, Y.; Shen, F.; et al. Rapid hemostasis tumor in situ hydrogel vaccines for colorectal cancer chemo-immunotherapy. ACS. Appl. Mater. Interfaces. 2024, 16, 61679-91.
179. Ji, P.; Sun, W.; Zhang, S.; et al. Modular hydrogel vaccine for programmable and coordinate elicitation of cancer immunotherapy. Adv. Sci. 2023, 10, e2301789.
180. Zhao, X.; Xuan, F.; Li, Z.; et al. A KIF20A-based thermosensitive hydrogel vaccine effectively potentiates immune checkpoint blockade therapy for hepatocellular carcinoma. NPJ. Vaccines. 2025, 10, 1.
181. Wang, Z. L.; Qiu, S. Y.; Sun, Y. Q.; et al. An injectable oncolytic hydrogel platform for in situ dendritic cell vaccination to boost antitumor immunity. Biomater. Sci. 2025, 13, 3016-29.
182. Kenny, H. A.; Krausz, T.; Yamada, S. D.; Lengyel, E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int. J. Cancer. 2007, 121, 1463-72.
183. Fischbach, C.; Chen, R.; Matsumoto, T.; et al. Engineering tumors with 3D scaffolds. Nat. Methods. 2007, 4, 855-60.
184. Gao, H.; Korn, J. M.; Ferretti, S.; et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 2015, 21, 1318-25.
185. Tian, Y. F.; Ahn, H.; Schneider, R. S.; et al. Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials 2015, 73, 110-9.
186. Duan, Y.; Jin, Y.; Jia, Y.; et al. Fully synthetic nanofibrillar hydrogel for the growth and enzyme-free release of patient-derived ovarian tumor organoids. Biomaterials 2026, 326, 123723.
187. Gjorevski, N.; Sachs, N.; Manfrin, A.; et al. Designer matrices for intestinal stem cell and organoid culture. Nature 2016, 539, 560-4.
188. Ng, S.; Tan, W. J.; Pek, M. M. X.; Tan, M. H.; Kurisawa, M. Mechanically and chemically defined hydrogel matrices for patient-derived colorectal tumor organoid culture. Biomaterials 2019, 219, 119400.
189. Cruz-Acuña, R.; Kariuki, S. W.; Sugiura, K.; et al. Engineered hydrogel reveals contribution of matrix mechanics to esophageal adenocarcinoma and identifies matrix-activated therapeutic targets. J. Clin. Invest. 2023, 133, e168146.
190. Mosquera, M. J.; Kim, S.; Bareja, R.; et al. Extracellular matrix in synthetic hydrogel-based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 Inhibitors. Adv. Mater. 2022, 34, e2100096.
191. Rice, A. J.; Cortes, E.; Lachowski, D.; et al. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis 2017, 6, e352.
192. Tao, T.; Liu, H.; Gan, Z.; et al. A synthetic hydrogel with tunable stiffness for engineering pancreatic cancer organoids and drug testing. ACS. Biomater. Sci. Eng. 2025, 11, 5000-11.
193. Cavo, M.; Caria, M.; Pulsoni, I.; Beltrame, F.; Fato, M.; Scaglione, S. A new cell-laden 3D Alginate-Matrigel hydrogel resembles human breast cancer cell malignant morphology, spread and invasion capability observed “in vivo”. Sci. Rep. 2018, 8, 5333.
194. Jung, Y. H.; Choi, D. H.; Park, K.; et al. Drug screening by uniform patient derived colorectal cancer hydro-organoids. Biomaterials 2021, 276, 121004.
195. Prince, E.; Cruickshank, J.; Ba-Alawi, W.; et al. Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids. Nat. Commun. 2022, 13, 1466.
196. LeSavage, B. L.; Zhang, D.; Huerta-López, C.; et al. Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids. Nat. Mater. 2024, 23, 1138-49.
197. Luo, X.; Fong, E. L. S.; Zhu, C.; et al. Hydrogel-based colorectal cancer organoid co-culture models. Acta. Biomater. 2021, 132, 461-72.
198. Zhao, Y.; Gong, J.; Liu, H.; Huang, H.; Tan, W. S.; Cai, H. A chemically defined, mechanically tunable, and bioactive hyaluronic acid/alginate double-network hydrogel for liver cancer organoid construction. Int. J. Biol. Macromol. 2024, 282, 136707.
199. Jung, M.; Poltavets, V.; Skhinas, J. N.; et al. High-throughput 3D engineered paediatric tumour models for precision medicine. Mol. Syst. Biol. 2025, 21, 1748-77.
200. Miebach, L.; Hagge, M.; Hübner, L.; Bekeschus, S. Protocol for generating a 3D hydrogel-based tumor resection model in vitro using pancreatic cancer cells. STAR. Protoc. 2026, 7, 104416.
201. Zhang, S.; Lv, R.; Zhang, Z.; Wang, Z.; Jin, Z. Advancements in hydrogel-based embolic agents: categorized by therapeutic mechanisms. Cancer. Med. 2024, 13, e70183.
202. Lee, S. Y.; Choi, J. W.; Hwang, C.; et al. Intravascular casting radiopaque hydrogel systems for transarterial chemo/cascade catalytic/embolization therapy of hepatocellular carcinoma. Small 2024, 20, e2400287.
203. Xu, H.; Ohulchanskyy, T. Y.; Yakovliev, A.; et al. Nanoliposomes co-encapsulating CT imaging contrast agent and photosensitizer for enhanced, imaging guided photodynamic therapy of cancer. Theranostics 2019, 9, 1323-35.
204. Lee, S. M.; Yoo, S. Y.; Kim, T.; et al. Radiopaque hydrogel-in-liposomes towards theranostic applications for malignant tumors. Biomed. Pharmacother. 2025, 183, 117822.
205. Wang, B.; Hu, S.; Teng, Y.; et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal. Transduct. Target. Ther. 2024, 9, 200.
206. Hamad, H. T. Benzothiazole derivatives in cancer treatment: synthesis and therapeutic potential: review. MedMat 2025, 2, 17-32.
207. Lee, K. K.; Lee, J. H.; Lee, S. C.; Lee, C. S. MnCO3-mineralized polydopamine nanoparticles as an activatable theranostic agent for dual-modality imaging-guided photothermal therapy of cancers. Theranostics 2022, 12, 6762-78.
208. Ryu, J. H.; Koo, H.; Sun, I. C.; et al. Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy. Adv. Drug. Deliv. Rev. 2012, 64, 1447-58.
209. Dessale, M.; Mengistu, G.; Mengist, H. M. Nanotechnology: a promising approach for cancer diagnosis, therapeutics and theragnosis. Int. J. Nanomedicine. 2022, 17, 3735-49.
210. Annigeri, N. C.; Mohan, R.; Vijayakumar, D. B.; Lingaraj, A. J. Theragnosis using fluorescence: a review. J. Adv. Dental. Pract. Res. 2024, 2, 59-61.
211. Jirvankar, P.; Agrawal, S.; Chambhare, N.; Agrawal, R. Harnessing biopolymer gels for theranostic applications: imaging agent integration and real-time monitoring of drug delivery. Gels 2024, 10, 535.
212. Gao, Z.; Zhang, Y.; Liu, Q.; Ding, D. Mechanism and design of organic afterglow luminescent probes for cancer theranostics. MedMat 2024, 1, 27-39.
213. Wang, S.; Ma, R.; Mei, Z.; Hou, Y. Metalloptosis: metal ions-induced programmed cell death based on nanomaterials for cancer therapy. MedMat 2024, 1, 6-26.
214. Mantooth, S. M.; Green, J. M.; Green, W. D.; et al. An injectable hydrogel enhances intratumoral retention and antitumor efficacy of cytokine immunotherapy in murine triple negative breast tumor models. J. Control. Release. 2025, 383, 113761.
215. Vu, T. T.; Jo, S. H.; Kim, S. H.; Kim, B. K.; Park, S. H.; Lim, K. T. Injectable and multifunctional hydrogels based on poly(N-acryloyl glycinamide) and alginate derivatives for antitumor drug delivery. ACS. Appl. Mater. Interfaces. 2024, 16, 15322-35.
216. Liang, S.; Wang, T.; Ding, J.; Yang, J.; He, C.; Rong, Y. Injectable matrix metalloproteinase-responsive polypeptide hydrogels as drug depots for antitumor chemo-immunotherapy. Pharmaceutics 2025, 17, 1453.
217. Gierlich, P.; Donohoe, C.; Behan, K.; Kelly, D. J.; Senge, M. O.; Gomes-da-Silva, L. C. Antitumor immunity mediated by photodynamic therapy using injectable chitosan hydrogels for intratumoral and sustained drug delivery. Biomacromolecules 2024, 25, 24-42.
218. Wang, Y.; Pan, H.; Meng, Z.; Zhang, C. In situ biosynthesis of photothermal parasite for fluorescence imaging-guided photothermal therapy of tumors. Gels 2022, 8, 754.
219. Xu, Y.; Wang, F.; Liu, W.; et al. Aggregation-induced-emission luminogens functionalized MXene nanosheets for stimuli-responsive hydrogel in pyroptosis-mediated choroidal melanoma therapy. Nanomicro. Lett. 2026, 18, 282.
220. Heng, C.; Zheng, X.; Hui, J.; Ma, X.; Fan, D. Neodymium and manganese ions co-doped whitlockite for temperature monitoring, photothermal therapy, and bone tissue repair in osteosarcoma. J. Colloid. Interface. Sci. 2024, 653, 1488-503.
221. Lee, W. T.; Yoon, J.; Kim, S. S.; et al. Combined antitumor therapy using in situ injectable hydrogels formulated with albumin nanoparticles containing indocyanine green, chlorin e6, and perfluorocarbon in hypoxic tumors. Pharmaceutics 2022, 14, 148.
222. Peng, Z.; Li, M.; Wang, Y.; et al. Self-assembling imageable silk hydrogels for the focal treatment of osteosarcoma. Front. Cell. Dev. Biol. 2022, 10, 698282.
223. Liu, M.; Sun, Y.; Zhou, Y.; et al. A novel coacervate embolic agent for tumor chemoembolization. Adv. Healthc. Mater. 2024, 13, e2304488.
224. Peng, Y.; Liu, H.; Liang, X.; et al. Self-assembling chemodrug fiber-hydrogel for transarterial chemoembolization and radiotherapy-enhanced antitumor immunity. J. Control. Release. 2025, 380, 1-16.
225. Dong, Y. C.; Nieves, L. M.; Hsu, J. C.; et al. Novel combination treatment for melanoma: FLASH radiotherapy and immunotherapy delivered by a radiopaque and radiation responsive hydrogel. Chem. Mater. 2023, 35, 9542-51.
226. Delgado, J. F.; Pritchard, W. F.; Varble, N.; et al. X-ray imageable, drug-loaded hydrogel that forms at body temperature for image-guided, needle-based locoregional drug delivery. Sci. Rep. 2024, 14, 13352.
227. Som, A.; Rosenboom, J. G.; Wehrenberg-Klee, E.; et al. Percutaneous intratumoral immunoadjuvant Gel increases the abscopal effect of cryoablation for checkpoint inhibitor resistant cancer. Adv. Healthc. Mater. 2024, 13, e2301848.
228. Ranjbar-Navazi, Z.; Fathi, M.; Abdolahinia, E. D.; Omidi, Y.; Davaran, S. MUC-1 aptamer conjugated InP/ZnS quantum dots/nanohydrogel fluorescent composite for mitochondria-mediated apoptosis in MCF-7 cells. Mater. Sci. Eng. C. Mater. Biol. Appl. 2021, 118, 111469.
229. Wang, Y.; Wu, J.; Chen, M.; et al. Application of near-infrared-activated and ATP-responsive trifunctional upconversion nano-jelly for in vivo tumor imaging and synergistic therapy. Biosens. Bioelectron. 2024, 250, 116094.
230. Shuhendler, A. J.; Staruch, R.; Oakden, W.; et al. Thermally-triggered ‘off-on-off’ response of gadolinium-hydrogel-lipid hybrid nanoparticles defines a customizable temperature window for non-invasive magnetic resonance imaging thermometry. J. Control. Release. 2012, 157, 478-84.
231. Zhou, Y.; Shu, G.; Luo, Y.; et al. Achieving complete tumor clearance: a minimalist manganese hydrogel for magnetic resonance imaging-guided synergetic microwave ablation and chemodynamic therapy. Adv. Healthc. Mater. 2024, 13, e2303268.
232. Shazeeb, M. S.; Corazzini, R.; Konowicz, P. A.; et al. Assessment of in vivo degradation profiles of hyaluronic acid hydrogels using temporal evolution of chemical exchange saturation transfer (CEST) MRI. Biomaterials 2018, 178, 326-38.
233. Dorsey, S. M.; Haris, M.; Singh, A.; et al. Visualization of injectable hydrogels using chemical exchange saturation transfer MRI. ACS. Biomater. Sci. Eng. 2015, 1, 227-37.
234. Zhu, W.; Chu, C.; Kuddannaya, S.; et al. In vivo imaging of composite hydrogel scaffold degradation using CEST MRI and two-color NIR imaging. Adv. Funct. Mater. 2019, 29, 1903753.
235. Park, S. W.; Lai, J. H. C.; Han, X.; et al. Preclinical application of CEST MRI to detect early and regional tumor response to local brain tumor treatment. Pharmaceutics 2024, 16, 101.
236. Lusic, H.; Grinstaff, M. W. X-ray-computed tomography contrast agents. Chem. Rev. 2013, 113, 1641-66.
237. Li, X.; Ullah, M. W.; Li, B.; Chen, H. Recent progress in advanced hydrogel-based embolic agents: from rational design strategies to improved endovascular embolization. Adv. Healthc. Mater. 2023, 12, e2202787.
238. Isaac, E. I.; Hall, J.; Dault, J. B.; Elbich, J.; McGhee, A.; Fields, E. C. Transarterial chemoembolization with LC bead LUMI followed by stereotactic body radiation therapy in treatment of hepatocellular carcinoma. Adv. Radiat. Oncol. 2022, 7, 100830.
239. Mikhail, A. S.; Pritchard, W. F.; Negussie, A. H.; et al. Cone-beam computed tomography-based spatial prediction of drug dose after transarterial chemoembolization using radiopaque drug-eluting beads in woodchuck hepatocellular carcinoma. Invest. Radiol. 2022, 57, 495-501.
240. Bakos, O.; Lawson, C.; Rouleau, S.; Tai, L. H. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J. Immunother. Cancer. 2018, 6, 86.
241. Pantel, K.; Alix-Panabières, C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat. Rev. Clin. Oncol. 2025, 22, 65-77.
242. Løberg, M.; Lousdal, M. L.; Bretthauer, M.; Kalager, M. Benefits and harms of mammography screening. Breast. Cancer. Res. 2015, 17, 63.
243. Schiffman, J. D.; Fisher, P. G.; Gibbs, P. Early detection of cancer: past, present, and future. Am. Soc. Clin. Oncol. Educ. Book. 2015, 57-65.
244. Feng, Z.; Wu, J.; Lu, Y.; et al. Circulating tumor cells in the early detection of human cancers. Int. J. Biol. Sci. 2022, 18, 3251-65.
245. Crosby, D.; Bhatia, S.; Brindle, K. M.; et al. Early detection of cancer. Science 2022, 375, eaay9040.
246. Zhang, Y.; Wang, T.; Tian, Y.; et al. Gold nanorods-mediated efficient synergistic immunotherapy for detection and inhibition of postoperative tumor recurrence. Acta. Pharm. Sin. B. 2021, 11, 1978-92.
247. Sun, L.; Shen, F.; Tian, L.; et al. ATP-responsive smart hydrogel releasing immune adjuvant synchronized with repeated chemotherapy or radiotherapy to boost antitumor immunity. Adv. Mater. 2021, 33, e2007910.
248. Zhao, H.; Song, Q.; Zheng, C.; et al. Implantable bioresponsive nanoarray enhances postsurgical immunotherapy by activating pyroptosis and remodeling tumor microenvironment. Adv. Funct. Mater. 2020, 30, 2005747.
249. Wang, D.; Liu, J.; Duan, J.; et al. Enrichment and sensing tumor cells by embedded immunomodulatory DNA hydrogel to inhibit postoperative tumor recurrence. Nat. Commun. 2023, 14, 4511.
250. Geng, S.; Guo, P.; Wang, J.; et al. Ultrasensitive optical detection and elimination of residual microtumors with a postoperative implantable hydrogel sensor for preventing cancer recurrence. Adv. Mater. 2024, 36, e2307923.
251. Li, X.; Li, R.; Wang, F.; et al. Theranostic hydrogels: construction strategies and applications. Chem. Eng. J. 2025, 505, 159545.
252. Maitz, M. F.; Freudenberg, U.; Tsurkan, M. V.; Fischer, M.; Beyrich, T.; Werner, C. Bio-responsive polymer hydrogels homeostatically regulate blood coagulation. Nat. Commun. 2013, 4, 2168.
253. Jiang, Y.; Trotsyuk, A. A.; Niu, S.; et al. Wireless, closed-loop, smart bandage with integrated sensors and stimulators for advanced wound care and accelerated healing. Nat. Biotechnol. 2023, 41, 652-62.
254. Mostafalu, P.; Tamayol, A.; Rahimi, R.; et al. Smart bandage for monitoring and treatment of chronic wounds. Small 2018, 14, e1703509.
255. Xu, G.; Lu, Y.; Cheng, C.; et al. Battery‐free and wireless smart wound dressing for wound infection monitoring and electrically controlled on‐demand drug delivery. Adv. Funct. Mater. 2021, 31, 2100852.
256. Ge, Z.; Guo, W.; Tao, Y.; et al. Wireless and closed-loop smart dressing for exudate management and on-demand treatment of chronic wounds. Adv. Mater. 2023, 35, e2304005.
257. Yang, C.; Sheng, T.; Hou, W.; et al. Glucose-responsive microneedle patch for closed-loop dual-hormone delivery in mice and pigs. Sci. Adv. 2022, 8, eadd3197.
258. Zheng, X.; Sun, W.; Ju, M.; Wu, J.; Huang, H.; Shen, B. A chemical biology toolbox to overcome the hypoxic tumor microenvironment for photodynamic therapy: a review. Biomater. Sci. 2022, 10, 4681-93.
259. Corbet, C.; Feron, O. Tumour acidosis: from the passenger to the driver’s seat. Nat. Rev. Cancer. 2017, 17, 577-93.
260. Gorrini, C.; Harris, I. S.; Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug. Discov. 2013, 12, 931-47.
261. Singleton, D. C.; Macann, A.; Wilson, W. R. Therapeutic targeting of the hypoxic tumour microenvironment. Nat. Rev. Clin. Oncol. 2021, 18, 751-72.
262. Zhao, F.; Zhao, Z.; Gao, H.; et al. Cuproptosis: an emerging domain for copper-based nanomaterials mediated cancer therapy. MedMat 2024, 1, 74-94.
263. Chen, J.; Larsson, L.; Swarbrick, A.; Lundeberg, J. Spatial landscapes of cancers: insights and opportunities. Nat. Rev. Clin. Oncol. 2024, 21, 660-74.
264. Beeghly, G. F.; Shimpi, A. A.; Riter, R. N.; Fischbach, C. Measuring and modelling tumour heterogeneity across scales. Nat. Rev. Bioeng. 2023, 1, 712-30.
265. Brindle, K. New approaches for imaging tumour responses to treatment. Nat. Rev. Cancer. 2008, 8, 94-107.
266. Abramson, A.; Chan, C. T.; Khan, Y.; et al. A flexible electronic strain sensor for the real-time monitoring of tumor regression. Sci. Adv. 2022, 8, eabn6550.
267. Shah, B. A.; Sardar, A.; Li, Y.; Yang, B. Shining light on immunotherapy in metastatic urothelial carcinoma: trends and prospects. MedMat 2025, 2, 240-52.
268. Lin, C. C.; Metters, A. T. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv. Drug. Deliv. Rev. 2006, 58, 1379-408.
269. Murdan, S. Electro-responsive drug delivery from hydrogels. J. Control. Release. 2003, 92, 1-17.
271. Kim, H. J.; Koo, J. H.; Lee, S.; Hyeon, T.; Kim, D. Materials design and integration strategies for soft bioelectronics in digital healthcare. Nat. Rev. Mater. 2025, 10, 654-73.
272. Subba, S. H.; Park, S. Y. In situ cancer-cell-triggered visible changes in mechanical properties, electroconductivity, and adhesiveness of a MnO2@PD-based mineralized hydrogel. ACS. Appl. Mater. Interfaces. 2023, 15, 38357-66.
273. Qu, J.; Xie, K.; Chen, S.; et al. Multifunctional hydrogel electronics for closed-loop antiepileptic treatment. Sci. Adv. 2024, 10, eadq9207.
274. Yoo, H.; Kang, S. B.; Kim, J.; et al. Ionic diode-based drug delivery system. Adv. Mater. 2025, 37, e2412377.
275. Cui, H.; An, B.; Li, Z.; Li, J. Dynamic bonds enabled hydrogel adhesives: advancing ophthalmic repair and regeneration. MedMat 2025, 2, 188-94.
276. Wang, J.; Hou, J.; Lu, H.; et al. Engineering programmable nanobiomaterials (PNBMs) for cancer nanotherapy. MedMat 2025, 2, 1-16.
277. Mndlovu, H.; Kumar, P.; du Toit, L. C.; Choonara, Y. E. A review of biomaterial degradation assessment approaches employed in the biomedical field. npj. Mater. Degrad. 2024, 8, 66.
278. Longmire, M.; Choyke, P. L.; Kobayashi, H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 2008, 3, 703-17.
279. Tsoi, K. M.; MacParland, S. A.; Ma, X. Z.; et al. Mechanism of hard-nanomaterial clearance by the liver. Nat. Mater. 2016, 15, 1212-21.
280. Dong, Y. C.; Bouché, M.; Uman, S.; Burdick, J. A.; Cormode, D. P. Detecting and monitoring hydrogels with medical imaging. ACS. Biomater. Sci. Eng. 2021, 7, 4027-47.
281. Mariani, E.; Lisignoli, G.; Borzì, R. M.; Pulsatelli, L. Biomaterials: foreign bodies or tuners for the immune response? Int. J. Mol. Sci. 2019, 20, 636.
282. Butenko, S.; Nagalla, R. R.; Guerrero-Juarez, C. F.; et al. Hydrogel crosslinking modulates macrophages, fibroblasts, and their communication, during wound healing. Nat. Commun. 2024, 15, 6820.
283. Gavish Moscovitz, A.; Simaan Yameen, H.; Bar-Am, O.; Seliktar, D. Evaluating cross-linking efficiency and cytocompatibility of three commonly used photoinitiators across different cell-compatible hydrogel platforms. Biomacromolecules 2025, 26, 6817-33.
284. U.S. Food and Drug Administration. 510(k) premarket notification: MARKIT Tissue Marker (K121964). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K121964. (accessed 2026-09-16).
285. U.S. Food and Drug Administration. 510(k) premarket notification: HydroMARK Breast Biopsy Site Marker (K212158). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?id=K212158. (accessed 2026-09-16).
286. Mandal, A.; Clegg, J. R.; Anselmo, A. C.; Mitragotri, S. Hydrogels in the clinic. Bioeng. Transl. Med. 2020, 5, e10158.
287. Saputri, R. I.; Mensah, A.; Rodgers, A. M.; et al. Hydrogel-based devices for cancer diagnostics: a systematic review of materials and biomarkers. Future. Sci. OA. 2025, 11, 2587305.
288. U.S. Food and Drug Administration. Orphan drug designations and approvals: JELMYTO (Mitomycin). https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=445114. (accessed 2026-09-16).
289. U.S. Food and Drug Administration. FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mitomycin-intravesical-solution-recurrent-low-grade-intermediate-risk-non-muscle. (accessed 2026-09-16).
290. U.S. Food and Drug Administration. Premarket approval: Embrace Hydrogel Embolic System (P250003). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P250003. (accessed 2026-09-16).
291. U.S. Food and Drug Administration. Device classification under section 513(f)(2) (de novo): SpaceOAR System (DEN140030). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN140030. (accessed 2026-09-16).
292. U.S. Food and Drug Administration. 510(k) premarket notification: Barrigel Injectable Gel (K220641). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?id=K220641. (accessed 2026-09-16).
293. Clegg, J. R.; Adebowale, K.; Zhao, Z.; Mitragotri, S. Hydrogels in the clinic: an update. Bioeng. Transl. Med. 2024, 9, e10680.
294. Abi-Jaoudeh, N.; Chen, J.; Dey, C.; et al. Multicenter randomized trial evaluating the safety and effectiveness of the instylla hydrogel embolic system for vascular occlusion of hypervascular tumors. J. Vasc. Interv. Radiol. 2026, 37, 108946.
295. Wang, F.; Chen, J.; Liu, J.; Zeng, H. Cancer theranostic platforms based on injectable polymer hydrogels. Biomater. Sci. 2021, 9, 3543-75.
296. Wu, H.; Piao, G.; Chen, Q.; et al. Hydrogels: current biomedical applications and future directions. Mol. Biomed. 2026, 7, 123.
297. Carballo-Pedrares, N.; Giménez, V. M. M.; Alonso, M. J. Clinical translation of injectable hydrogels: from bioactive polymers to long-acting drug delivery systems. Drug. Deliv. Transl. Res. 2026, 16, 1685-708.
298. U.S. Food and Drug Administration. Frequently asked questions about combination products. https://www.fda.gov/combination-products/about-combination-products/frequently-asked-questions-about-combination-products. (accessed 2026-09-16).
299. National Cancer Institute. Immune checkpoint inhibitors. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors. (accessed 2026-09-16).
300. Viola, M.; Sequeira, J.; Seiça, R.; et al. Subcutaneous delivery of monoclonal antibodies: how do we get there? J. Control. Release. 2018, 286, 301-14.
301. U.S. Food and Drug Administration. Approved cellular and gene therapy products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products. (accessed 2026-09-16).
302. National Cancer Institute. CAR T cells: engineering patients’ immune cells to treat their cancers. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells. (accessed 2026-09-16).
303. Kelley, B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009, 1, 443-52.
304. Gao, Y.; Cho, H. J. Quantifying the trade-off between stiffness and permeability in hydrogels. Soft. Matter. 2022, 18, 7735-40.
305. Chavda, H.; Patel, C. Effect of crosslinker concentration on characteristics of superporous hydrogel. Int. J. Pharm. Investig. 2011, 1, 17-21.
306. Lee, S.; Tong, X.; Yang, F. The effects of varying poly(ethylene glycol) hydrogel crosslinking density and the crosslinking mechanism on protein accumulation in three-dimensional hydrogels. Acta. Biomater. 2014, 10, 4167-74.
307. Lee, S.; Tong, X.; Yang, F. Effects of the poly(ethylene glycol) hydrogel crosslinking mechanism on protein release. Biomater. Sci. 2016, 4, 405-11.
308. Alix-Panabières, C.; Pantel, K. Liquid biopsy: from discovery to clinical application. Cancer. Discov. 2021, 11, 858-73.
309. Liu, L.; Liu, J.; Zhou, W.; et al. An artificial antibody for exosome capture by dull template imprinting technology. J. Mater. Chem. B. 2022, 10, 6655-63.
310. Liu, L.; Dong, C.; Li, X.; et al. Antibody-free hydrogel with the synergistic effect of cell imprinting and boronate affinity: toward the selective capture and release of undamaged circulating tumor cells. Small 2020, 16, e1904199.
311. Zuo, H.; Jiao, Y.; Chen, J.; Tong, S.; Li, Y.; Zhao, W. Recent advances in smart stimulus-responsive hydrogels for precision drug delivery in tumours. Gels 2026, 12, 98.
312. Ding, H.; Tan, P.; Fu, S.; et al. Preparation and application of pH-responsive drug delivery systems. J. Control. Release. 2022, 348, 206-38.
313. Xue, W.; Wang, L.; Yi, K.; Sun, L.; Ren, H.; Bian, F. Hepatocellular carcinoma biomarkers screening based on hydrogel photonic barcodes with tyramine deposition amplified ELISA. Biosens. Bioelectron. 2024, 255, 116270.
314. Zorrón, M.; Cabrera, A. L.; Sharma, R.; et al. Emerging 2D nanomaterials-integrated hydrogels: advancements in designing theragenerative materials for bone regeneration and disease therapy. Adv. Sci. 2024, 11, e2403204.
315. Shen, C.; Wang, Y.; Xiao, X.; et al. Hydrogels for in vivo biomedical applications: recent advances and future perspectives. J. Mater. Chem. B. 2026, 14, 2386-406.
316. Rodriguez-Rivera, G. J.; Green, M.; Shah, V.; Leyendecker, K.; Cosgriff-Hernandez, E. A user’s guide to degradation testing of polyethylene glycol-based hydrogels: from in vitro to in vivo studies. J. Biomed. Mater. Res. A. 2024, 112, 1200-12.
317. Schneider, E. L.; Henise, J.; Reid, R.; Ashley, G. W.; Santi, D. V. Hydrogel drug delivery system using self-cleaving covalent linkers for once-a-week administration of exenatide. Bioconjug. Chem. 2016, 27, 1210-5.
318. Herrmann, A.; Haag, R.; Schedler, U. Hydrogels and their role in biosensing applications. Adv. Healthc. Mater. 2021, 10, e2100062.
319. Han, X.; Huang, J.; To, A. K. W.; et al. CEST MRI detectable liposomal hydrogels for multiparametric monitoring in the brain at 3T. Theranostics 2020, 10, 2215-28.
320. Guan, Y.; Zhao, J.; Hou, S.; et al. Fluorescent self-reporting theranostic platforms for tumour therapy: from cytotoxin release monitoring to therapeutic feedback evaluation. J. Mater. Chem. B. 2026, 14, 5836-58.
321. Garcia-Garcia, A.; Muñana-González, S.; Lanceros-Mendez, S.; Ruiz-Rubio, L.; Alvarez, L. P.; Vilas-Vilela, J. L. Biodegradable natural hydrogels for tissue engineering, controlled release, and soil remediation. Polymers 2024, 16, 2599.
322. Dagogo-Jack, I.; Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 2018, 15, 81-94.
323. Sobczak, M. Enzyme-responsive hydrogels as potential drug delivery systems-state of knowledge and future prospects. Int. J. Mol. Sci. 2022, 23, 4421.
324. Zhang, Y.; Xu, Y.; Wei, C.; et al. Diselenide-containing poly(ε-caprolactone)-based thermo-responsive hydrogels with oxidation and reduction-triggered degradation. Mater. Today. Chem. 2017, 4, 172-9.
325. Huang, W.; Wu, X.; Zhao, Y.; et al. Janus-inspired core-shell structure hydrogel programmatically releases melatonin for reconstruction of postoperative bone tumor. ACS. Appl. Mater. Interfaces. 2023, 15, 2639-55.
326. Komatsu, H.; Matsumoto, S.; Tamaru, S.; Kaneko, K.; Ikeda, M.; Hamachi, I. Supramolecular hydrogel exhibiting four basic logic gate functions to fine-tune substance release. J. Am. Chem. Soc. 2009, 131, 5580-5.
327. Badeau, B. A.; Comerford, M. P.; Arakawa, C. K.; Shadish, J. A.; DeForest, C. A. Engineered modular biomaterial logic gates for environmentally triggered therapeutic delivery. Nat. Chem. 2018, 10, 251-8.
328. Liu, G. F.; Ji, W.; Feng, C. L. Installing logic gates to multiresponsive supramolecular hydrogel co-assembled from phenylalanine amphiphile and bis(pyridinyl) derivative. Langmuir 2015, 31, 7122-8.
329. Webber, M. J.; Tibbitt, M. W. Dynamic and reconfigurable materials from reversible network interactions. Nat. Rev. Mater. 2022, 7, 541-56.
330. Picchioni, F.; Muljana, H. Hydrogels based on dynamic covalent and non covalent bonds: a chemistry perspective. Gels 2018, 4, 21.
331. Cao, L. Q.; Xie, Y.; Liu, Y.; Wurpel, J.; Zeng, L.; Chen, Z. S. Application of cancer organoids: the forefront of personalized oncology and preclinical testing. Organoid. Res. 2025, 1, 025050008.
